Earnings Call Summary | Exagen(XGN.US) Q4 2023 Earnings Conference
Earnings Call Summary | Exagen(XGN.US) Q4 2023 Earnings Conference
The following is a summary of the Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript:
以下是Exagen Inc.（XGN）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Exagen reported a record full-year revenue of $52.5 million for 2023, a 15% increase over 2022.
Q4 revenues accounted for $13.8 million of the total annual revenue.
The company saw an improvement in gross margin to 56% for the full year of 2023, and over 59% for the 4th quarter. They aim to reach a target of 60% gross margins.
A significant improvement was also seen in the adjusted EBITDA year-over-year, which increased by $22 million or 57%.
Exagen報告稱，2023年全年收入創歷史新高，達到5,250萬美元，比2022年增長15％。
第四季度的收入佔年總收入的1,380萬美元。
該公司的毛利率在2023年全年提高到56％，第四季度的毛利率超過59％。他們的目標是達到毛利率60％的目標。
調整後的息稅折舊攤銷前利潤同比增長了2200萬美元，增長了57％。
Business Progress:
業務進展：
Exagen reported record deliveries of 137,000 AVISE CTD tests in 2023, including about 30,000 in the fourth quarter.
The average selling price of AVISE CTD testing increased by 18%, from $285 at the end of 2022 to $336 in 2023.
The company announced plans to launch new proprietary T cell markers within the AVISE CTD platform in 2024. These markers are expected to identify up to 50% of SLE patients who would test negative by standard care testing.
Patent protection for these markers will last through 2035 and are projected to improve the company's financial performance by the end of 2024.
For 2024, growth is expected to be primarily driven by average selling price (ASP), with an increase in testing volumes also anticipated.
The company has set ambitious goals to achieve a gross margin of around 60% and revenue of approximately $75 million with their current cash balance.
Exagen報告稱，2023年AVISE CTD測試的交付量創紀錄的13.7萬次，其中包括第四季度的約3萬次。
AVISE CTD測試的平均銷售價格上漲了18％，從2022年底的285美元上漲到2023年的336美元。
該公司宣佈計劃於2024年在AVISE CTD平台內推出新的專有T細胞標誌物。預計這些標誌物將識別出高達50％的系統性紅斑狼瘡患者，這些患者通過標準護理測試呈陰性。
這些標誌的專利保護將持續到2035年，預計到2024年底將改善公司的財務業績。
預計2024年的增長將主要由平均銷售價格（ASP）推動，預計測試量也將增加。
該公司設定了雄心勃勃的目標，以目前的現金餘額實現約60％的毛利率和約7500萬美元的收入。
More details: Exagen IR
更多詳情： Exagen 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。